Cancer Cell Patents (Class 424/155.1)
  • Patent number: 11007212
    Abstract: The present invention relates to a microbubble complex comprising a microbubble having an outer shell comprising a mixture of native and denatured albumin encapsulating a perfluorocarbon gas, a therapeutic agent, a bifunctional linker having one end attached to the therapeutic agent and the other attached to a ligand and wherein the ligand is bound to the other shell of the microbubble through hydrophobic interactions. Also included are methods for delivering the aforementioned microbubble complex to a tissue target.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: May 18, 2021
    Inventors: Anup Sood, Lisa Anne Lowery, Praveena Mohan, James Edward Rothman, John Donald Burczak, Hae Won Lim
  • Patent number: 11007271
    Abstract: Provided herein is a conjugate comprising two residues of structurally and/or mechanistically different anticancer bioactive agents, coupled to one another by a biocleavable linking moiety, as well as methods of treating cancer using the same and pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: May 18, 2021
    Assignee: Ariel Scientific Innovations Ltd.
    Inventors: Gary Gellerman, Yosi Gilad, Helena Tuchinsky
  • Patent number: 10947316
    Abstract: An immunoconjugate includes an anti-Globo H antibody, or a binding fragment thereof, and a therapeutic agent or a label, having the formula: Ab?(L?D)m, wherein Ab is the anti-Globo H antibody or the binding fragment thereof, L is a linker or a direct bond, D is the therapeutic agent or the label, and m is an integer from 1 to 8. The antibody may be a monoclonal antibody, which may be a humanized antibody. A method for treating a cancer includes administering to a subject in need of such treatment a pharmaceutically effective amount of an immunoconjugate containing an antibody against Globo H, or a binding fragment thereof, and a therapeutic agent covalently conjugated with the antibody.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: March 16, 2021
    Assignee: Development Center for Biotechnology
    Inventors: Chao-Pin Lee, Shih-Hsien Chuang, Chuan-Lung Hsu, Yi-Jen Chen, Yu-Chin Nieh, Win-Yin Wei, Chia-Cheng Wu
  • Patent number: 10920270
    Abstract: Methods and compositions are provided for improved nucleic acid amplification assays. In some embodiments, the nucleic acid amplification assay is a tagged amplicon primer extension (TAPE) nucleic acid amplification reaction.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: February 16, 2021
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Nicholas Heredia, Dianna Maar
  • Patent number: 10918698
    Abstract: A novel and thermostable lyophilized pharmaceutical composition of Romiplostim (Fcpeptide fusion protein) along with buffer, bulking agent, stabilizer, and surfactant at pH range of 4.0-6.0.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: February 16, 2021
    Inventors: Himanshu Gadgil, Chandresh Chhatbar, Vijaykant Pandey
  • Patent number: 10913786
    Abstract: The present disclosure relates to isolated polypeptides that inhibit Wnt signaling, pharmaceutical compositions comprising the isolated polypeptides, and methods of use thereof. Nucleic acids, cells, and methods of production related to the isolated polypeptides and compositions are also disclosed.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: February 9, 2021
    Assignee: Children's Medical Center Corporation
    Inventors: Min Dong, Liang Tao
  • Patent number: 10905717
    Abstract: The invention relates to treating individuals with cancer by using blood plasma or blood plasma fractions as treatment.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: February 2, 2021
    Assignee: Alkahest, Inc.
    Inventors: Steven P. Braithwaite, S. Sakura Minami, Joseph McCracken
  • Patent number: 10858438
    Abstract: This invention relates to binding molecules that bind specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin-17 (CDH17) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of cancer.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: December 8, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus-Peter Kuenkele, Timothy Fenn, Juan Manuel Garcia-Martinez, Jason Ho, Christian Koessl, Saurabh Sen, Vladimir Voynov, Andreas Wernitznig
  • Patent number: 10799597
    Abstract: The present invention relates to methods of cancer therapy using subcutaneous administration of antibody-drug conjugates (ADCs). Preferably, the ADC comprises an antibody that binds to Trop-2, CEACAM5, CEACAM6, CD20, CD22, CD30, CD46, CD74, Her-2, folate receptor, or HLA-DR. More preferably, the drug is SN-38. Subcutaneous administration is at least as effective as intravenous administration of the same ADC. Surprisingly, subcutaneous administration can be used without inducing unmanageable adverse local toxicity at the injection site. Subcutaneous administration is advantageous in requiring less frequent administration, substantially reducing the amount of time required for intravenous administration, and reducing the levels of systemic toxicities observed with intravenous administration.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: October 13, 2020
    Assignee: Immunomedics, Inc.
    Inventor: David M. Goldenberg
  • Patent number: 10800856
    Abstract: This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are ?PSMA antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the ?PSMA antibodies of the invention are conjugated to one or more toxins. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, dolastatin analogs, and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: October 13, 2020
    Assignee: Ambrx, Inc.
    Inventors: Richard S. Barnett, Feng Tian, Anna-Maria A. Hays Putnam, Marco Gymnopoulos, Nick Knudsen, Andrew Beck, Ying Sun
  • Patent number: 10759868
    Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a 5T4 monoclonal antibody, conferring specific immunity against 5T4 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia, and for solid tumors such as colon, stomach, and ovarian tumors.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: September 1, 2020
    Assignee: CELLECTIS
    Inventor: Cècile Schiffer-Mannioui
  • Patent number: 10731221
    Abstract: The invention relates to classification, diagnosis and treatment of cancers. In one embodiment, the present invention provides methods and kits that classify cancers into various subtypes based on expression patterns of AKT pathway components. In another embodiment, the present invention provides methods and kits that diagnose cancer subtypes by evaluating expression patterns of AKT pathway components. In still another embodiment, the present invention provides methods and kits that treat a cancer subtype by administering an alkylating agent or a PI3K/AKT/mTOR inhibitor to a patient. Cancers suitable with various embodiments of the invention include but are not limited to brain tumors, gliomas and GBM.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: August 4, 2020
    Assignee: Dignity Health
    Inventors: Anna Joy, Burt G. Feuerstein, Ivan Smirnov
  • Patent number: 10689447
    Abstract: Described herein are Fc variants and methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins). Heteromultimeric proteins may be capable of specifically binding to more than one target. The targets may be, for example, different epitopes on a single molecule or located on different molecules. The methods combine efficient, high gene expression level, appropriate assembly, and ease of purification for the heteromultimeric proteins. The invention also provides methods of using these heteromultimeric proteins, and compositions, kits and articles of manufacture comprising these antibodies.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: June 23, 2020
    Assignee: Genentech, Inc.
    Inventors: J. Michael Elliott, Justin Scheer
  • Patent number: 10682400
    Abstract: The present invention comprises compositions, methods, and devices for enhancing an endogenous immune response against a cancer. Devices and methods provide therapeutic immunity to subjects against cancer.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: June 16, 2020
    Assignees: President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.
    Inventors: Omar Abdel-Rahman Ali, David J. Mooney, Glenn Dranoff
  • Patent number: 10670603
    Abstract: The present invention relates to methods of using the expression of ILTL3 ligand or ILT3 on certain types of cancer cells as a diagnostic tool. Methods are provided for treating ILT3-ligand expressing cancers, such as T-cell acute lymphoblastic leukemia (T-cell acute lymphoblastic leukemia), for example by administering ILT3, the extracellular domain of ILT3 or ILT3Fc conjugated to a cytotoxic agent to kill the targeted cancer cell. Other methods are provided for treating cancers that express ILT3 on their surface, such as monocytic forms of AML, for example by administering anti-ILT3 antibodies conjugated to a cytotoxic agent.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: June 2, 2020
    Inventors: Nicole Suciu-Foca, George Vlad, Chih-Chao Chang, Zhuoru Liu, Adriana Ioana Colovai
  • Patent number: 10620096
    Abstract: The present invention contemplates use of encapsulated aqueous and non-aqueous reagents, solutions and solvents and their use in laboratory procedures. These encapsulated aqueous or non-aqueous reagents, solutions and solvents can be completely contained or encapsulated in microcapsules or nanocapsules that can be added to an aqueous or non-aqueous carrier solution or liquid required for medical and research laboratory testing of biological or non-biological specimens.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: April 14, 2020
    Inventor: Lee H. Angros
  • Patent number: 10611812
    Abstract: Disclosed is a tumor-targeting fusion protein comprising at least (i) a IL-15 peptide or a variant or functional fragment thereof, (ii) a IL-15R? polypeptide or a variant or functional fragment thereof, (iii) a Fc domain or a variant or functional fragment thereof, and (iv) a RGD polypeptide or a variant thereof. The fusion protein is preferably configured as RGD polypeptide-Fc domain-IL-15 polypeptide-IL-15R? polypeptide. The tumor-targeting fusion proteins provided herein improves the anti-tumor effects of IL-15 and prolongs the half-life of IL-15, while targeting tumor sites and acting upon tumor cells. In addition, the fusion proteins are capable of being expressed at high efficiency and purified. The high efficiency of anti-tumor activity enables the fusion proteins to be an excellent candidate for tumor immunotherapy.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: April 7, 2020
    Assignee: Numab Biopharmaceuticals (Hangzhou) Ltd.
    Inventors: Zhong Wang, Qing Li
  • Patent number: 10607152
    Abstract: Evaluations of a document are generated that indicate likelihoods of the document achieving its objectives. The evaluations are based on predictive characteristics of one or more outcomes of the client document that are indicative of whether the document will achieve its objectives. Specifically, a server receives the document from a client device. The server extracts a set of features from the document. The evaluations of the document are generated based on the predictive characteristics for the one or more outcomes of the document. The generated evaluations are provided to the client device such that the document can be optimized to achieve its desired objectives. The optimized document may also be sent to a posting server for posting to a computer network. The known outcomes of the optimized document are collected through reader responses to the document and analyzed to improve evaluations for other documents.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: March 31, 2020
    Assignee: Textio, Inc.
    Inventors: Kieran Snyder, Robert E. Kolba, Jr., Jensen Harris
  • Patent number: 10570454
    Abstract: The invention provides the identification of oncogenic pathways activated in cytologically normal airway cells of individuals having or at risk of having lung disease, as well as specific gene expression patterns (biomarkers) associated with pathway activation. These biomarkers and pathways may provide prognostic and/or diagnostic indicators in lung disease, e.g., lung cancer. Additionally, these pathways and biomarkers may provide therapeutic targets for the treatment of lung disease, as well as markers for the assessment of treatment efficacy.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: February 25, 2020
    Assignees: Trustees of Boston University, University of Utah Research Foundation
    Inventors: Jerome S. Brody, Avrum Spira, Adam Gustafson, Andrea Bild
  • Patent number: 10543254
    Abstract: Provided is a composition containing neuropeptide Y for inhibiting side effects of anticancer agents. The neuropeptide Y of the present invention exhibits an effect of mitigating side effects, especially bone marrow injury and neurological disorders, occurring due to the administration of anticancer agents, and thus may be useful as an anticancer adjuvant which may mitigate side effects of anticancer agents and enhance the effect of anticancer agents.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: January 28, 2020
    Inventors: Jae Sung Bae, Hee Kyung Jin, Min Hee Park
  • Patent number: 10507244
    Abstract: Provided herein are antigen-binding proteins (ABPs) that selectively bind to TIGIT and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: December 17, 2019
    Assignee: Potenza Therapeutics, Inc.
    Inventors: Daniel Hicklin, William Winston, Cynthia Seidel-Dugan, Nels P. Nielson
  • Patent number: 10493128
    Abstract: The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: December 3, 2019
    Assignee: Heat Biologics, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • Patent number: 10471122
    Abstract: A pharmaceutical composition for use in promoting wound healing and/or accelerating closure of an open wound in a subject in need thereof is disclosed. The composition comprises a therapeutically effective amount of a recombinant polypeptide comprising an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO: 2; and a pharmaceutically acceptable vehicle, carrier, diluent, excipients, and/or salt.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: November 12, 2019
    Assignee: Blue Blood Biotech Corp.
    Inventors: Guey-Yueh Shi, Kuan-Chieh Wang, Yi-Kai Hong, Chih-Yuan Ma, Hua-Lin Wu
  • Patent number: 10441607
    Abstract: In some aspects, the present disclosure provides compositions comprising an N4-based MMC ligand, a cell targeting group, and a fluorophore or a therapeutic compound comprising a formula: wherein the variables are as defined herein. In some embodiments, these compositions may be used in the imaging techniques or in the treatment of a disease or disorder such as cancer.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: October 15, 2019
    Inventors: Ali Azhdarinia, Sukhen C. Ghosh, Nathaniel L. Wilganowski, Eva M. Sevick-Muraca
  • Patent number: 10434153
    Abstract: Modified T-cells have paratopes against human TK1 epitopes, are made by producing monoclonal antibodies that are specific to TK1, creating chimeric antigen receptors (CARs) by fusion of the single-chain variable fragments (scFv) of the monoclonal antibodies to T-cell signalling domains, and transducing the CARs to the T-cells.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: October 8, 2019
    Inventors: Kim Leslie O'Neill, Scott Weber
  • Patent number: 10391146
    Abstract: Compositions and methods for inhibiting metastatic cancer cells. The compositions comprise nanoparticles which have incorporated therein leukocyte adhesion molecules and therapeutic molecules exposed on their surface. The nanoparticles may be provided attached to leukocytes. Introduction of these compositions in to the circulation of individuals results in inhibition and reduction of metastatic cancer cells.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: August 27, 2019
    Assignee: Cornell University
    Inventors: Michael R. King, Michael J. Mitchell, Kuldeepsinh Rana, Elizabeth C. Wayne, Chris B. Schaffer, Siddarth Chandrasekaran
  • Patent number: 10350266
    Abstract: The present invention provides a method of treating cancer with an integrin-binding-Fc fusion protein alone or in combination with IL-2 and/or an immune checkpoint inhibitor. The invention also provides composition for use in such methods.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: July 16, 2019
    Inventors: Jennifer R. Cochran, Karl Dane Wittrup
  • Patent number: 10338071
    Abstract: A repeatable method for detecting circulating tumor cells in vitro is provided. The method involves combining a test sample from a patient suspected of having circulating tumor cells, and a non-lytic adenoviral system, and culture media for the cells. The adenoviral system utilizes (i) a first replication-defective adenoviral particle in which an expression cassette is packaged, said expression cassette comprising an adenoviral 5? and 3? ITRs and a tumor-specific promoter; and (ii) a coding sequence for a reporter protein which is expressed in the presence of circulating tumor cells, and an adenoviral 3? ITR. The test sample and the non-lytic adenoviral system are incubated for a sufficient time to permit expression of the reporter protein, and measuring reporter protein expression in the test samples, whereby presence of reporter expression indicates the presence of circulating tumor cells in the sample. Because the system is non-lytic, the testing can be repeated on the cells which remain viable in culture.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: July 2, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Stephen M. Hahn, Jay F. Dorsey, Gary D. Kao, Emigdio Reyes
  • Patent number: 10328149
    Abstract: The present invention relates to a conjugate comprising an anti-EGFR1 antibody or an EGFR binding fragment thereof and at least one dextran derivative, wherein the dextran derivative comprises at least one D-glucopyranosyl unit, wherein at least one carbon selected from carbon 2, 3 or 4 of the at least one D-glucopyranosyl unit is substituted by a substituent of the formula —O—(CH2)n—S—B12H112? wherein n is in the range of 3 to 10; and the dextran derivative is bound to the anti-EGFR antibody or an EGFR1 binding fragment thereof via a bond formed by a reaction between at least one aldehyde group formed by oxidative cleavage of a D-glucopyranosyl unit of the dextran derivative and an amino group of the anti-EGFR1 antibody or an EGFR1 binding fragment thereof.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: June 25, 2019
    Assignee: TENBORON OY
    Inventors: Anne Leppanen, Filip S. Ekholm, Jari Helin, Hanna Salo, Anne Kanerva
  • Patent number: 10307479
    Abstract: This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of vaccines. This invention also provides a method of treating a subject comprising administrating the above pharmaceutical composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of natural antibodies. This invention provides a composition comprising effective amount of glucan capable of enhancing host immunity. This invention also provides a composition comprising effective amount of glucan capable of enhancing the action of an agent in preventing tissue rejection.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: June 4, 2019
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventor: Nai-Kong V. Cheung
  • Patent number: 10304219
    Abstract: A set of first modality data is provided to an intra-reconstruction motion correction method. The set of first modality data includes a plurality of views. A set of second modality data is provided to the method. A motion estimate is generated for each of the plurality of views in the set of first modality data by registering the set of first modality data with the set of second modality data. A motion corrected model of the set of first modality data is generated by a forward projection including the motion estimate.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: May 28, 2019
    Assignee: Siemens Medical Solutions USA, Inc.
    Inventors: Michal Cachovan, Alexander Hans Vija
  • Patent number: 10251906
    Abstract: In an aspect, the invention relates to compositions, methods, and kits for inducing apoptosis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: April 9, 2019
    Inventors: Jindrich Henry Kopecek, Jiyuan Yang, Te-Wei Chu
  • Patent number: 10245279
    Abstract: Method for immobilizing a target microorganism or target chemical found in a mammal includes introducing into a gastrointestinal tract of the mammal immobilization particles including immobilization molecules capable of attaching to the target microorganism or the target chemical, which immobilization molecules are attached to one or more portions of a structure that is capable of inhibiting contact between tissues of the gastrointestinal tract and the target microorganisms or target chemicals attached to the immobilization molecules.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: April 2, 2019
    Assignee: NuBiome, Inc.
    Inventor: Brian C. Lue
  • Patent number: 10179810
    Abstract: Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: January 15, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Paul Adam, Eric Borges, Robert Rauchenberger, Gabriela Wochnik-Veltrup
  • Patent number: 10118970
    Abstract: The invention provides multispecific antibodies and methods of making and using such antibodies. In general, the multispecific antibodies are made by methods involving the steps of altering the nucleic acid sequence encoding the light chain variable domain (VL) of an antibody that binds a first epitope, and selecting a multispecific antibody capable of binding the first and a second epitope.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: November 6, 2018
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Jenny M. Bostrom
  • Patent number: 10077316
    Abstract: The present invention relates to an esophageal cancer marker and application thereof. The present invention relates to: a marker that includes Glypican-1 or an expression product thereof, or a fragment or derivative thereof, and serves to identify esophageal cancer; a detection agent that includes a substance that binds to Glypican-1 or an expression product thereof; and a composition that includes a Glypican-1 inhibitor and serves to prevent or treat esophageal cancer. Herein, Glypican-1 can be SEQ ID NO: 1 (nucleic acid sequence) or SEQ ID NO: 2 (amino acid sequence), or an equivalent thereof.
    Type: Grant
    Filed: December 25, 2014
    Date of Patent: September 18, 2018
    Assignee: National University Corporation, Kochi University
    Inventors: Tetsuji Naka, Satoshi Serada, Minoru Fujimoto, Masayoshi Toyoura, Yuji Shoya
  • Patent number: 10072082
    Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: September 11, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: John P. Cogswell, Stacie M. Goldberg, Ashok K. Gupta, Maria Jure-Kunkel, Xi-Tao Wang, Jon M. Wigginton
  • Patent number: 10017767
    Abstract: An agent that increases YAP1 levels for use in the treatment of hematopoietic disorders.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: July 10, 2018
    Inventors: Giovanni Tonon, Francesca Cottini, Kenneth Carl Anderson
  • Patent number: 10000575
    Abstract: An antibody recognizing the O-acetylated-GD2 ganglioside for the treatment of Cancer Stem Cells (CSC) cancer, a pharmaceutical composition including the antibody for treating a CSC cancer and a method for treating a CSC cancer in a patient in need thereof, the method including administering the antibody to the patient. A method for diagnosing a CSC, the use of the O-acetylated-GD2 ganglioside as a biomarker of CSC cancer, and a method for predicting the response of a subject affected with CSC cancer to a treatment with the antibody or the composition are also described.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: June 19, 2018
    Inventors: Stephane Birkle, Denis Cochonneau, Mylene Dorvillius, Jean-Marc Le Doussal, Mickael Terme
  • Patent number: 9926377
    Abstract: The invention provides anti-GPC3 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: March 27, 2018
    Assignee: Genentech, Inc.
    Inventors: Paul Polakis, Youjun Chen
  • Patent number: 9890208
    Abstract: The present invention features compositions featuring agents that bind to denatured collagen and methods of using such agents to treat or prevent fibrosis or inflammation in a subject.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: February 13, 2018
    Assignee: Maine Medical Center
    Inventors: Peter C. Brooks, Leif Oxburgh, Jennifer M. Caron
  • Patent number: 9879267
    Abstract: Methods and compositions are provided to determine if a cancer is resistant to treatment with anti-mitotic agents, including treatment with T-DM1. The methods relate to determining if the ABCC3 gene is amplified and/or overexpressed in the cancer.
    Type: Grant
    Filed: March 12, 2009
    Date of Patent: January 30, 2018
    Assignee: Genentech, Inc.
    Inventors: Mark Lackner, Lukas C. Amler, Guy Cavet, Carol O'Brien, Ajay Pandita
  • Patent number: 9873915
    Abstract: The present disclosure provides methods and kits that can be used to determine the grade or stage of a breast or other cancer, such as a ductal carcinoma in situ (DCIS). By determining the grade, stage, or aggressiveness of a cancer, appropriate therapeutic regiments can be selected and administered to the patient with the cancer. The method includes detecting osteopontin-c (OPN-c), wherein the presence of high amounts of OPN-c in the cancer sample indicates that the subject has a more aggressive form of cancer (e.g., grade 3).
    Type: Grant
    Filed: October 16, 2008
    Date of Patent: January 23, 2018
    Assignees: Ventana Medical Systems, Inc., University of Cincinnati
    Inventors: Mana Mirza, Elizabeth Shaughnessy, Georg F. Weber, John K. Hurley, Kristie A. Vanpatten, Gary Pestano
  • Patent number: 9855291
    Abstract: Novel monoclonal antibodies that specifically bind to KAAG1 are described. In some embodiments, the antibodies block the biological activity of KAAG1 and are useful in composition in certain cancers, more particularly in cancers that have increased cell surface expression of KAAG1, such as ovarian, renal, lung, colorectal, breast, brain, and prostate cancer, as well as melanoma. The invention also relates to cells expressing the monoclonal antibodies and antigen binding fragments such as humanized and chimeric antibodies. Additionally, methods of detecting and treating cancer using the antibodies and fragments are also disclosed.
    Type: Grant
    Filed: November 3, 2009
    Date of Patent: January 2, 2018
    Assignee: ADC Therapeutics SA
    Inventors: Gilles Bernard Tremblay, Mario Filion, Traian Sulea
  • Patent number: 9844607
    Abstract: The invention relates to a companion diagnostic antibody-like binding protein based on the humanized monoclonal antibody, DS6, to be used as diagnostic tool for in vivo detection and quantification of the tumor-associated MUC1-sialoglycotope, CA6.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: December 19, 2017
    Inventors: Jochen Kruip, Sanjiv S. Gambhir, Susanta K. Sarkar, Mathias Gebauer, Christian Lange, Ingo Focken, Richard Kimura, Arutselvan Natarajan, Ohad Ilovich
  • Patent number: 9815897
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a programmed death-1 (PD-1) protein. The invention provides a PD-1-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the PD-1-binding agent to treat a cancer or an infectious disease.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: November 14, 2017
    Assignee: AnaptysBio, Inc.
    Inventors: David J. King, Marilyn Kehry
  • Patent number: 9803015
    Abstract: The invention features methods of diagnosis by assessing B7-H1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with B7-H1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of B7-H1.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: October 31, 2017
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Lieping Chen, Scott E. Strome, Eugene D. Kwon
  • Patent number: 9797906
    Abstract: Polypeptide marker antigens for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, each of the polypeptide marker antigens binding specifically to at least one autoantibody marker. An antibody binding assay for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, and methods for performing the assay. Methods for determining ovarian cancer recurrence in an ovarian cancer patient. A method for isolating antibodies specific for ovarian cancer by their affinity to the polypeptide marker antigens, and antibodies isolated by that method.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: October 24, 2017
    Assignee: Wayne State University
    Inventors: Michael Tainsky, Madhumita Chatterjee, Gregory Dyson, Nancy Levin
  • Patent number: 9797904
    Abstract: The present invention relates to a method for diagnosing the lung cancers such as non small lung cancer in a subject by using isocitrate dehydrogenase 1 as a diagnostic biomarker. The present invention also relates to a method for predicting the prognosis of the lung cancers such as non small lung cancer in a subject by using isocitrate dehydrogenase 1 as a prognostic biomarker. The present invention further relates to a method to suppress proliferation of lung tumor cells in a subject, decrease growth of lung tumor cells in a subject, or improve survival of a subject with lung cancer by using isocitrate dehydrogenase 1 as a therapeutic target.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: October 24, 2017
    Assignee: Cancer Hospital, Chinese Academy of Medical Sciences
    Inventors: Jie He, Fengwei Tan, Zhaoli Chen, Nan Sun
  • Patent number: 9789202
    Abstract: A method for preventing or treating a cancer includes administering an anti-cancer pharmaceutical composition including an interferon alpha or a polymer conjugate thereof. The pharmaceutical composition can be co-administered with anti-cancer agents. The interferon alpha conjugate shows a longer in vivo half-life and a more excellent anti-cancer activity than the conventional interferon alpha, and in particular, its co-administration with an anti-cancer agent such as gemcitabine has synergistic inhibitory effects on cancer cell growth and proliferation so as to exhibit a remarkably excellent anti-cancer activity. Further, the anti-cancer pharmaceutical composition has excellent in vivo half-life and anti-cancer activity to greatly reduce administration frequency.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: October 17, 2017
    Inventors: Sung Youb Jung, Young Eun Woo, Se Young Lim, In Young Choi, Jae Ho Lee, Se Chang Kwon, Sung Hwan Moon, Jiawang Liu